Saturday, 31 October 2026European Markets

NYRSTAR Stock Was Up By 9.24% Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with NYRSTAR (NYR.BR) rising 9.24% to €0.05 on Friday, after five successive sessions in a row of losses. BEL 20 dropped 0.49% to €3,983.85, following the last session's downward trend on what was a somewhat down trend trading session today.

NYRSTAR's last close was €0.05, 69.82% below its 52-week high of €0.17.

About NYRSTAR

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining of zinc and lead in Australia. The company was incorporated in 2007 and is based in Balen, Belgium.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-0.01.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYRSTAR's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for NYRSTAR is 4000 which is 90.29% below its average volume of 41196.

Sales Growth

NYRSTAR's sales growth is 4.5% for the ongoing quarter and 4.5% for the next.

Volatility

NYRSTAR's last week, last month's, and last quarter's current intraday variation average was a negative 3.39%, a negative 1.95%, and a positive 2.95%.

NYRSTAR's highest amplitude of average volatility was 3.39% (last week), 3.63% (last month), and 2.95% (last quarter).

More news about NYRSTAR (NYR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
NYRSTAR Stock Was Up By 9.24% Before The Weekend | ViaNews EU